|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG008063060 |
003 |
DE-627 |
005 |
20230425183156.0 |
007 |
cr uuu---uuuuu |
008 |
211221s2021 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG008063060
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2021-003237-11-DE
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)TMP-2005-2020-36
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Effect of Bronchipret on patient with mild Covid disease
|b Effect of Bronchipret on antiviral immune response in patients with mild COVID-19 (BroVID) - BroVID
|
264 |
|
1 |
|c 2021
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 02-08-2021, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Adult patients suffering from mild COVID-19 with cough and at least one other symptoms will be recruited for this study. MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862 MedDRA version: 20.0Level: PTClassification code 10011224Term: CoughSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 06. Dez.
|
773 |
1 |
8 |
|g year:2021
|g day:06
|g month:12
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-003237-11
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2021
|b 06
|c 12
|